Nexalin Technology
Nexalin Technology
NXL
NASDAQ
0.92
USD
-69.02%
About
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.
Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3).
Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 142.3K |
| Three Month Average Volume | 58.7M |
| High Low | |
| Fifty-Two Week High | 4.05 USD |
| Fifty-Two Week Low | 0.2528 USD |
| Fifty-Two Week High Date | 26 Jun 2024 |
| Fifty-Two Week Low Date | 13 Feb 2024 |
| Price and Volume | |
| Current Price | 0.9212 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -20.00% |
| Thirteen Week Relative Price Change | 22.96% |
| Twenty-Six Week Relative Price Change | 153.88% |
| Fifty-Two Week Relative Price Change | 65.02% |
| Year-to-Date Relative Price Change | 92.17% |
| Price Change | |
| One Day Price Change | -1.99% |
| Thirteen Week Price Change | 31.60% |
| Twenty-Six Week Price Change | 179.15% |
| Five Day Price Change | -4.40% |
| Fifty-Two Week Price Change | 106.78% |
| Year-to-Date Price Change | 127.57% |
| Month-to-Date Price Change | -19.90% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.4312 USD |
| Book Value Per Share (Most Recent Quarter) | 0.17808 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.41701 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.14828 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.85965 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.01505 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.02016 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.63187 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.72608 USD |
| Normalized (Last Fiscal Year) | -0.71547 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.63187 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.72608 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.63187 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.72608 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.39648 USD |
| Cash Per Share (Most Recent Quarter) | 0.11188 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.6313 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.7244 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.50514 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -2,505 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -3,598.50% |
| Pretax Margin (Last Fiscal Year) | -4,197.48% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 76.80% |
| Gross Margin (Trailing Twelve Months) | 82.94% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -4,588.07% |
| Operating Margin (Trailing Twelve Months) | -3,859.71% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -4,197.48% |
| Net Profit Margin (Trailing Twelve Months) | -3,598.50% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -24.48% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -76.89% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -23.03% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -51.79% |
| EPS Change (Trailing Twelve Months) | -117.36% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 9 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -848,800 |
| Net Debt (Last Fiscal Year) | -2,948,430 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 88 |
| Price to Sales (Trailing Twelve Months) | 65 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 5 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 8 |
| Quick Ratio (Most Recent Quarter) | 5 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 8 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -3,845,690 |
| Free Cash Flow (Trailing Twelve Months) | -3,761,700 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -84.03% |
| Return on Assets (Trailing Twelve Months) | -160.37% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -107.05% |
| Return on Equity (Trailing Twelve Months) | -202.23% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -106.99% |
| Return on Investment (Trailing Twelve Months) | -202.23% |
| Return on Investment (5 Year) | -99,999.99% |